Do not use semaglutide if: You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases
doi: 10.1371/journal.pone.0160221 Summary Keywords GLP-1 receptor agonists, gastrointestinal toxicities, adverse drug reactions, pharmacovigilance, data mining Citation Liu L, Chen J, Wang L, Chen C and Chen L (2022) Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database
For instance, the most likely possibility may be, as mentioned before, the liver presenting BPC 157 beneficial effect on various liver lesions including CCl4 hepatotoxicity (29-31)